Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 BioNTech, MediLink Therapeutics Ink Global ADC Alliance | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

BioNTech, MediLink Therapeutics Ink Global ADC Alliance

BioNTech to pay $70 million upfront and additional development, regulatory and commercial milestones, with a potential value of more than $1 billion.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

BioNTech entered into a strategic research collaboration and worldwide licensing agreement with MediLink Therapeutics based in China, to develop next-generation antibody-drug conjugates for cancer. BioNTech will pay $70 million upfront and additional development, regulatory and commercial milestones, with a potential value of more than $1 billion.
 
MediLink will grant the exclusive global right to develop, manufacture and commercialize its antibody-drug conjugate (ADC) assets targeting the HER3 protein, and will retain ownership of these molecules in the Greater China region.
 
HER3 is a tyrosine kinase receptor that is often over-expressed in several solid tumors, including breast, ovarian and prostate cancers. According to MediLink, HER3 is a well-validated target in cancer and is closely associated with tumor metastasis and disease progression.
 
MediLink is developing HER3-directed ADCs using its TMALIN platform designed to overcome challenges such as the need to be absorbed by lysosomes and large molecule size, which lower permeability. TMALIN uses a unique ADC structure with novel digestion characteristics to allow the therapeutic to exert its effects on the tumor’s microenvironment, inducing a high concentration of the payload in tumor tissue and achieving strong cancer-killing activity.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics